These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37129285)

  • 1. Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy.
    Casadevall A; Joyner MJ; Pirofski LA; Senefeld JW; Shoham S; Sullivan D; Paneth N; Focosi D
    Expert Rev Respir Med; 2023 May; 17(5):381-395. PubMed ID: 37129285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
    Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
    Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?
    Bloch EM; Tobian AAR; Shoham S; Hanley DF; Gniadek TJ; Cachay ER; Meisenberg BR; Kafka K; Marshall C; Heath SL; Shenoy A; Paxton JH; Levine A; Forthal D; Fukuta Y; Huaman MA; Ziman A; Adamski J; Gerber J; Cruser D; Kassaye SG; Mosnaim GS; Patel B; Metcalf RA; Anjan S; Reisler RB; Yarava A; Lane K; McBee N; Gawad A; Raval JS; Zand M; Abinante M; Broderick PB; Casadevall A; Sullivan D; Gebo KA
    Transfusion; 2022 May; 62(5):933-941. PubMed ID: 35352362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
    Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Plasma for the Treatment of COVID-19: Lessons Learned so far.
    Schrezenmeier H; Hoffmann S; Hofmann H; Appl T; Jahrsdörfer B; Seifried E; Körper S
    Hamostaseologie; 2023 Feb; 43(1):67-74. PubMed ID: 36807822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
    De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
    Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.
    Herman JD; Wang C; Burke JS; Zur Y; Compere H; Kang J; Macvicar R; Taylor S; Shin S; Frank I; Siegel D; Tebas P; Choi GH; Shaw PA; Yoon H; Pirofski LA; Julg BD; Bar KJ; Lauffenburger D; Alter G
    Cell Rep Med; 2022 Nov; 3(11):100811. PubMed ID: 36351430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.
    Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P
    Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID 19 convalescent plasma: Is there still a place for CCP?
    Moog R
    Transfus Apher Sci; 2023 Apr; 62(2):103680. PubMed ID: 36870907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019.
    Bloch EM; Focosi D; Shoham S; Senefeld J; Tobian AAR; Baden LR; Tiberghien P; Sullivan DJ; Cohn C; Dioverti V; Henderson JP; So-Osman C; Juskewitch JE; Razonable RR; Franchini M; Goel R; Grossman BJ; Casadevall A; Joyner MJ; Avery RK; Pirofski LA; Gebo KA
    Clin Infect Dis; 2023 Jun; 76(11):2018-2024. PubMed ID: 36740590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.
    Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM
    Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
    Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
    Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.
    Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.
    Yılmaz S; Ertuğrul Örüç N; Özcebe Oİ; Azap A; Çetin AT; Yenicesu İ; Öztürk A; Gündüz M; Tekin A
    Transfus Apher Sci; 2020 Oct; 59(5):102846. PubMed ID: 32593519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Assessment of Convalescent Plasma Efficacy against COVID-19.
    Casadevall A; Grossman BJ; Henderson JP; Joyner MJ; Shoham S; Pirofski LA; Paneth N
    Med; 2020 Dec; 1(1):66-77. PubMed ID: 33363284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
    Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D
    Nat Commun; 2022 Oct; 13(1):6478. PubMed ID: 36309490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
    Bihariesingh-Sanchit R; Bansie R; Ramdhani N; Mangroo R; Bustamente D; Diaz E; Fung A Foek C; Thakoer I; Vreden S; Choudhry Z; van 't Wout AB; Diavatopoulos DA; Nierich AP
    mBio; 2023 Apr; 14(2):e0337922. PubMed ID: 36815780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns.
    Chen B; Xia R
    Vox Sang; 2020 Aug; 115(6):507-514. PubMed ID: 32516839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors.
    Leon J; Merrill AE; Rogers K; Kurt J; Dempewolf S; Ehlers A; Jackson JB; Knudson CM
    Transfus Apher Sci; 2022 Apr; 61(2):103326. PubMed ID: 34862140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.